~~<i id='0A0CB1AAAB'><strike id='0A0CB1AAAB'><tt id='0A0CB1AAAB'><pre id='0A0CB1AAAB'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

hotspot

focus

author：Wikipedia 2025-09-27 23:53:44 - browse：1

AP/Richard Drew

Johnson & Johnson said Monday that it would purchase Ambrx Biopharma for nearly $2 billion, picking up a company specializing in targeted chemotherapy treatments — one of the hottest areas of cancer drug development.

The deal, disclosed as the biopharma field marked the first day of the annual J.P. Morgan Healthcare Conference, extends a recent spate of pharma acquisitions, contributing to hopes that 2024 could be a better year for the industry.

Under the agreement, J&J will pay $28 per share in cash for Ambrx, roughly a 100% premium to the latter’s recent trading price.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： The Readout: Lisata, Eisai x Biogen, and the Met Gala (!)

Wikipedia

focus

entertainment

hotspot

focus

hotspot

2:42PresidentJoeBidenspeaksintheEastRoomoftheWhiteHouseinWashington,July25,2023.SusanWalsh/APPreside

WSS

5 wounded, 2 critically, in Michigan shopping center shooting

Military medical care influenced by rank and race, new study finds

Wellcome Trust’s new CEO hopes Big Tech gets more involved in public health

5 wounded, 2 critically, in Michigan shopping center shooting

Addiction experts warn against a second 'war on drugs'

What AstraZeneca

hotspot

focus

Wikipedia

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Judge orders hearing on Trump's motion to disqualify Fulton County DA

Affirmative action in medical school literally saved lives

Criminal prosecution for violating HIPAA: an emerging threat

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Helping hospitals and community health centers plan for resilience

United colonoscopy coverage change 'may cost lives,' doctors say

Fla. should 'correct' controversial slavery curriculum: Republican Rep. Byron Donalds

The cancer drug shortage isn’t new — and neither are the solutions

Philippine ferry was overloaded when it flipped over, leaving 27 dead, official says

focus

Wellcome Trust’s new CEO hopes Big Tech gets more involved in public health

Addiction experts warn against a second 'war on drugs'

Doctors increasingly discourage vaping amid mounting health concerns

Cytokinetics CEO stresses company can launch heart drug on its own

Trump team launching legal defense fund to help pay legal bills

5 wounded, 2 critically, in Michigan shopping center shooting

entertainment

hotspot

focus

hotspot